View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 14, 2022

Nykode concludes subject enrolment in Phase II cervical cancer vaccine trial

The multicentre, open-label trial enrolled subjects with advanced or recurrent, non-resectable HPV16-positive cervical cancer.

Nykode Therapeutics has concluded the subject enrolment in the Phase II VB C-02 clinical trial of its cancer vaccine candidate, VB10.16, plus atezolizumab to treat advanced cervical cancer. 

Interim efficacy and safety results from the trial are anticipated in the first half of this year.

An off-the-shelf therapeutic HPV16 cancer vaccine, VB10.16 can potentially elicit robust human papillomavirus 16 (HPV16)-specific T cell responses to treat cancers that are positive for HPV16.

Atezolizumab is a checkpoint inhibitor of Roche.

The multicentre, open-label trial enrolled advanced or recurrent, non-resectable HPV16-positive cervical cancer patients. 

Nealy 20 study centres have enrolled 50 participants in six European countries as part of the trial. 

Earlier, the company had reported positive interim safety results from this trial.

Nykode Therapeutics CEO Michael Engsig said: “After successfully enrolling 50 patients across trial sites in six countries, we look forward to reporting interim efficacy and safety data from the first patients in the first half of 2022. 

“In parallel, we are exploring the possibility of evaluating VB10.16 in other HPV-driven cancers, including head and neck cancer.”

Apart from the VB10.16 vaccine, the company has a cancer neoantigen vaccine, VB10.NEO.

Licensed exclusively to Genentech, VB10.NEO is currently being analysed in Phase Ib trial to treat locally advanced and metastatic tumours, as well as a Phase I/IIa trial to treat melanoma, lung, head and neck, renal and bladder cancers. 

Nykode commenced a Phase I/II trial of its two Covid-19 vaccine candidates last year.

Last December, the company dosed the first subject in Phase I/II VB-D-01 trial of its T cell-specific Covid-19 vaccine candidate in unvaccinated individuals.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU